Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients
Florian D. Hastert,
Lisa Henss,
Christine von Rhein,
Julia Gerbeth,
Imke Wieters,
Frauke Borgans,
Yascha Khodamoradi,
Kai Zacharowski,
Gernot Rohde,
Maria J.G.T. Vehreschild,
Barbara S. Schnierle
Affiliations
Florian D. Hastert
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany
Lisa Henss
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany
Christine von Rhein
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany
Julia Gerbeth
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany
Imke Wieters
Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Frauke Borgans
Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Yascha Khodamoradi
Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Kai Zacharowski
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Zentrum für Innere Medizin, Infektiologie, Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
Barbara S. Schnierle
Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strass 51-59, 63225 Langen, Germany
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has now been continuing for more than two years. The infection causes COVID-19, a disease of the respiratory and cardiovascular system of variable severity. Here, the humoral immune response of 80 COVID-19 patients from the University Hospital Frankfurt/Main, Germany, was characterized longitudinally. The SARS-CoV-2 neutralization activity of serum waned over time. The neutralizing potential of serum directed towards the human alpha-coronavirus NL-63 (NL63) also waned, indicating that no cross-priming against alpha-coronaviruses occurred. A subset of the recovered patients (n = 13) was additionally vaccinated with the mRNA vaccine Comirnaty. Vaccination increased neutralization activity against SARS-CoV-2 wild-type (WT), Delta, and Omicron, although Omicron-specific neutralization was not detectable prior to vaccination. In addition, the vaccination induced neutralizing antibodies against the more distantly related SARS-CoV-1 but not against NL63. The results indicate that although SARS-CoV-2 humoral immune responses induced by infection wane, vaccination induces a broad neutralizing activity against multiple SARS-CoVs, but not to the common cold alpha-coronavirus NL63.